

## LIST OF TABLES

<b>Table No.</b>	<b>Title of the table</b>	<b>Page No.</b>
3.1	Design of Piperazine substituted 1, 4-Naphthoquinone derivatives	68
3.2	Design of Oxadiazole substituted 1, 4-Naphthoquinone derivatives	72
4.1	Synthesis of compound with different substituted piperazines	73
4.2	Synthesis of compounds with different substituted oxadiazoles	74
4.3	Animal groups for <i>in-vivo</i> antitumor activity studies	83
5.1	Chemical structure of various piperazines substituted 1, 4-naphthoquinone derivatives (MB-1 to MB-19)	86
5.2	Chemical structure of various 1,3,4- oxadiazole substituted 1,4-naphthoquinone derivatives (MB-20 to MB-33)	100
5.3	Molecular docking score of compounds (MB-1 to MB-33)	112
5.4	QikProp analysis of compound MB-9,MB-24,MB-18 and MB-32	113
5.5	<i>In-vitro</i> cytotoxicity of piperazine substituted 2-methyle 1,4-naphthoquinone derivative (MB-1to MB-19)	115
5.6	<i>In-vitro</i> cytotoxicity of 1,3,4-Oxadiazole 2-methyle 1,4-naphthouinone of compounds MB-20 to MB-33	116
5.7	<i>In -vitro</i> inhibitory activities (IC <sub>50</sub> ) of synthesized compound (MB-20 to MB-33) against EGFR tyrosine kinase	118
5.8	LD <sub>50</sub> values of selected compounds	119
5.9	Anticancer activity of selected compounds at the dose of 5mg/kg (i.p.) in MNU induced breast cancer bearing rats	122
5.10	Anticancer effect of compound MB-9 and MB-24 at different doses on MNU induced breast cancer bearing rats	123